A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia
Jeffrey E. Lancet(Cornell University), Branimir I. Šikić(Stanford Medicine), George E. Durán(Palo Alto University), Maria R. Baer(University of Maryland, Baltimore), John F. Marcelletti(Stanford University), Alan F. List(TE Laboratories (Ireland)), Robert M. Fielding, Pratik S. Multani(Ignyta (United States))
Cited by 51
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k